Most Read Articles
Dr Margaret Shi, 14 Nov 2019

The triplet regimen of encorafenib, binimetinib and cetuximab provides significant and clinically relevant benefits in overall survival (OS) and objective response rate (ORR) in patients with BRAFV600E-mutated metastatic colorectal cancer (mCRC) who experience disease progression after one or two previous regimens, according to results of an interim analysis of the BEACON CRC trial.

Pank Jit Sin, 30 Oct 2017
Barely has the dust settled on e-cigarettes before the next cigarette replacement product, based on the heat-not-burn (HNB) principle, emerges to derail tobacco control efforts. 
Natalia Reoutova, 18 Sep 2019

A retrospective analysis of seven clinical trials demonstrated that neratinib-based therapy is safe and effective in Asian patients with metastatic HER2-positive breast cancer.

6 days ago
New drug applications approved by US FDA as of 01 - 15 November 2019 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date. 

Ultrasonic spectrum analysis noninvasively predicts malignant/benign lesions in lung cancer patients

26 Sep 2019

A recent study has suggested the use of spectrum analysis of endobronchial ultrasound (EBUS) radiofrequency in predicting malignant or benign peripheral pulmonary lesions (PPL) noninvasively in patients with lung cancer.

“Analysis of the ‘intercept’ of the targeted lesion may provide useful supporting data for real‐time sampling from PPL during diagnostic bronchoscopy,” the authors said.

Seventy-one PPL were analysed, of which 45 were malignant lesions and 26 benign. Malignant PPL had a significantly lower intercept (p<0.0001), lower midband-fit (p<0.0001) and higher slope (p=0.014) compared with benign PPL.

Of the three parameters, intercept showed the best diagnostic performance (0.87 for intercept, 0.77 for midband-fit and 0.69 for slope) in analyses of the area under the curve of receiver operating characteristic plots.

The corresponding sensitivity, specificity, accuracy, and positive and negative likelihood were 75.6 percent, 96.2 percent, 83.1 percent, 19.6 and 0.25 for the intercept; 88.9 percent, 57.7 percent, 77.5 percent, 2.1 and 0.19 for the midband-fit; and 68.9 percent, 73.1 percent, 70.4 percent, 2.6 and 0.43 for the slope.

In this study, the authors prospectively recorded raw radial‐probe EBUS images with radiofrequency data, including backscatter signals. They computed the ultrasonic spectral parameters (ie, intercept, midband-fit and slope) within the region of interest using linear regression analysis and compared these with the final diagnosis.

“Analysis of the EBUS radiofrequency spectrum has been used for convex‐probe EBUS technology,” according to the authors. “Quantitative imaging analysis is also warranted for guided bronchoscopy using radial‐probe EBUS targeting PPL.”

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Dr Margaret Shi, 14 Nov 2019

The triplet regimen of encorafenib, binimetinib and cetuximab provides significant and clinically relevant benefits in overall survival (OS) and objective response rate (ORR) in patients with BRAFV600E-mutated metastatic colorectal cancer (mCRC) who experience disease progression after one or two previous regimens, according to results of an interim analysis of the BEACON CRC trial.

Pank Jit Sin, 30 Oct 2017
Barely has the dust settled on e-cigarettes before the next cigarette replacement product, based on the heat-not-burn (HNB) principle, emerges to derail tobacco control efforts. 
Natalia Reoutova, 18 Sep 2019

A retrospective analysis of seven clinical trials demonstrated that neratinib-based therapy is safe and effective in Asian patients with metastatic HER2-positive breast cancer.

6 days ago
New drug applications approved by US FDA as of 01 - 15 November 2019 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.